Close

Anti-CD20 T cell receptor (A94), pCDTCR1 (TCR-L129)

The vector of anti-CD20 T cell receptor (TCR) is constructed for the engineering of T cell to target Human CD20. The vector product was designed for the treatment of Multiple sclerosis (MS) (relapsing remitting).

Datasheet   Add to Cart

Details

  • Target
  • CD20
  • Target Species
  • Human
  • Epitope
  • SLFLGILSV
  • Format
  • Soluble T-cell receptor
  • HLA
  • HLA-A2
  • Targeting Diseases
  • Multiple sclerosis (MS) (relapsing remitting)
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • TCR Clone
  • A94
  • TCR Host Animal
  • Human

Target

  • Official Symbol
  • MS4A1
  • Introduction
  • This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry
Products

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive the latest news and insights to your inbox.